Share on StockTwits

RXi Pharmaceuticals Corp (NASDAQ:RXII) posted its quarterly earnings results on Thursday. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.02, Analyst Ratings.Net reports.

RXi Pharmaceuticals Corp (NASDAQ:RXII) opened at 2.69 on Thursday. RXi Pharmaceuticals Corp has a 52-week low of $2.21 and a 52-week high of $6.84. The stock has a 50-day moving average of $2.62 and a 200-day moving average of $3.71. The company’s market cap is $37.7 million.

On the ratings front, analysts at Laidlaw initiated coverage on shares of RXi Pharmaceuticals Corp in a research note on Monday, June 2nd. They set a “buy” rating and a $8.00 price target on the stock.

RXi Pharmaceuticals Corporation (NASDAQ:RXII) is a development-stage company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.